DDInter973 DDInter1763
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Irinotecan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Irinotecan {u} (Compound) downregulates {v} (Gene) MYC
MYC {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Irinotecan {u} (Compound) upregulates {v} (Gene) LRP10
LRP10 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Irinotecan {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Irinotecan {u} (Compound) upregulates {v} (Gene) LRPAP1
LRPAP1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Irinotecan {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Irinotecan {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Febrile neutropenia {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Irinotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Irinotecan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Irinotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Irinotecan (Compound) downregulates MYC (Gene) and MYC (Gene) is upregulated by Temsirolimus (Compound)
Irinotecan (Compound) upregulates LRP10 (Gene) and LRP10 (Gene) is upregulated by Temsirolimus (Compound)
Irinotecan (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Temsirolimus (Compound)
Irinotecan (Compound) upregulates LRPAP1 (Gene) and LRPAP1 (Gene) is downregulated by Temsirolimus (Compound)
Irinotecan (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is downregulated by Temsirolimus (Compound)
Irinotecan (Compound) causes Febrile neutropenia (Side Effect) and Febrile neutropenia (Side Effect) is caused by Temsirolimus (Compound)
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Irinotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)